ArticleJournal of inflammation research2026
Nomogram for Predicting Pancreatic Pseudocyst in Hypertriglyceridemic Acute Pancreatitis: A Retrospective Cohort Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Pancreatic pseudocyst (PPC) is a relatively common local complication of hypertriglyceridemic acute pancreatitis (HTG-AP), frequently associated with prolonged hospital stay and potentially increased need for minimally invasive intervention. However, there is currently no established PPC prediction tool based on early admission indicators for HTG-AP patients. Patients and Methods: In this retrospective study, 684 HTG-AP patients from January 2017 to January 2025 were included. All the patients were divided into training and validation sets in a 7:3 ratio. The least absolute shrinkage and selection operator regression was utilized for preliminary screening of predictive factors in the training set. Then, multivariate logistic regression was applied to identify potential factors for nomogram construction. Results: A total of 684 patients were included, with an overall PPC incidence of 15.7%. The model incorporated three predictors: systemic inflammatory response syndrome (SIRS) (odds ratio [OR] = 2.263, 95% confidence interval [CI]: 1.283-3.991, p = 0.005), C-reactive protein (CRP) (OR = 1.019, 95% CI: 1.013-1.026, p < 0.001), and lactate (OR = 3.219, 95% CI: 2.182-4.749, p < 0.001). The nomogram showed good discrimination, with an area under the curve (AUC) of 0.816 (95% CI: 0.759-0.869) in the training cohort and 0.760 (95% CI: 0.658-0.854) in the validation cohort. Calibration performance was acceptable, with calibration slopes of 1.000 and 0.773 and Brier scores of 0.100 and 0.108 in the training and validation cohorts, respectively. Decision curve analysis further demonstrated positive net clinical benefit in both cohorts. Conclusion: SIRS, CRP, and lactate may be associated with the occurrence of PPC in patients with HTG-AP and may have value for early risk assessment. We developed a nomogram for PPC risk stratification in this population; however, further external validation is needed to confirm its generalizability and potential clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.